{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:18:48Z","timestamp":1786119528366,"version":"build-2736575974"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1097\/hjh.0b013e32833984b8","type":"journal-article","created":{"date-parts":[[2010,7,7]],"date-time":"2010-07-07T03:54:07Z","timestamp":1278474847000},"page":"1595-1598","source":"Crossref","is-referenced-by-count":11,"title":["How should we manage heart failure developing in patients already treated with angiotensin-converting enzyme inhibitors and beta-blockers for hypertension, diabetes or coronary disease?"],"prefix":"10.1097","volume":"28","author":[{"given":"Finn","family":"Gustafsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Segura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis M","family":"Ruilope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-1-20210208","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1001\/jama.289.18.2363","article-title":"Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States","volume":"289","author":"Wolf-Maier","year":"2003","journal-title":"JAMA"},{"key":"R2-1-20210208","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1001\/archinte.167.2.141","article-title":"Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States","volume":"167","author":"Wang","year":"2007","journal-title":"Arch Intern Med"},{"key":"R3-1-20210208","doi-asserted-by":"crossref","first-page":"6A","DOI":"10.1016\/0735-1097(93)90455-A","article-title":"The epidemiology of heart failure: the Framingham Study","volume":"22","author":"Ho","year":"1993","journal-title":"J Am Coll Cardiol"},{"key":"R4-1-20210208","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/jama.1996.03530440037034","article-title":"The progression from hypertension to congestive heart failure","volume":"275","author":"Levy","year":"1996","journal-title":"JAMA"},{"key":"R5-1-20210208","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1053\/euhj.1998.1239","article-title":"Prevalence of heart failure and left ventricular dysfunction in the general population; The Rotterdam Study","volume":"20","author":"Mosterd","year":"1999","journal-title":"Eur Heart J"},{"key":"R6-1-20210208","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1093\/eurheartj\/ehn575","article-title":"Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis","volume":"30","author":"Verdecchia","year":"2009","journal-title":"Eur Heart J"},{"key":"R7-1-20210208","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"R8-1-20210208","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","article-title":"Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial","volume":"363","author":"Julius","year":"2004","journal-title":"Lancet"},{"key":"R9-1-20210208","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Dahlof","year":"2002","journal-title":"Lancet"},{"key":"R10-1-20210208","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.ejheart.2008.09.004","article-title":"Mode of death in patients with newly diagnosed heart failure in the general population","volume":"10","author":"Mehta","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"R11-1-20210208","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1161\/HYPERTENSIONAHA.108.125617","article-title":"Continued improvement in hypertension management in England: results fron the Health Survey for England 2006","volume":"53","author":"Falaschetti","year":"2009","journal-title":"Hypertension"},{"key":"R12-1-20210208","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1097\/HJH.0b013e3282f4edd7","article-title":"Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy","volume":"26","author":"Corrao","year":"2008","journal-title":"J Hypertens"},{"key":"R13-1-20210208","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0140-6736(05)17741-1","article-title":"Global burden of hypertension: analysis of worldwide data","volume":"365","author":"Kearney","year":"2005","journal-title":"Lancet"},{"key":"R14-1-20210208","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ahj.2004.12.005","article-title":"Effects of eplerenone versus losartan in patients with low-renin hypertension","volume":"150","author":"Weinberger","year":"2005","journal-title":"Am Heart J"},{"key":"R15-1-20210208","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/HJH.0b013e3281fc975a","article-title":"2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"25","author":"Mancia","year":"2007","journal-title":"J Hypertens"},{"key":"R16-1-20210208","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.mcna.2009.02.005","article-title":"Hypertension and cardiac failure in its various forms","volume":"93","author":"Gaddam","year":"2009","journal-title":"Med Clin North Am"},{"key":"R17-1-20210208","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcome Prevention Evaluation study investigators","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med"},{"key":"R18-1-20210208","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa042739","article-title":"Angiotensin-converting-enzyme inhibition in stable coronary artery disease","volume":"351","author":"Braunwald","year":"2004","journal-title":"N Engl J Med"},{"key":"R19-1-20210208","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","article-title":"Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)","volume":"362","author":"Fox","year":"2003","journal-title":"Lancet"},{"key":"R20-1-20210208","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1161\/01.CIR.0000054165.93055.42","article-title":"Prevention of heart failure in patients in the Heart Outcomes Prevention Evaluation (HOPE) study","volume":"107","author":"Arnold","year":"2003","journal-title":"Circulation"},{"key":"R21-1-20210208","first-page":"1429","article-title":"Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS trial study group.","volume":"316","year":"1987","journal-title":"N Engl J Med"},{"key":"R22-1-20210208","first-page":"293","article-title":"The SOLVD investigators.","volume":"325","year":"1991","journal-title":"N Engl J Med"},{"key":"R23-1-20210208","first-page":"V178","article-title":"Effect of enalapril, hydralazine plus isosorbide dinitrate, and prazosin on hospitalization in patients with chronic congestive heart failure. The V-HeFT VA Cooperative studies group","volume":"87","author":"Loeb","year":"1993","journal-title":"Circulation"},{"key":"R24-1-20210208","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJM200105313442201","article-title":"Effects of carvedilol on survival in severe chronic heart failure","volume":"344","author":"Packer","year":"2001","journal-title":"N Engl J Med"},{"key":"R25-1-20210208","first-page":"9","article-title":"II): a randomised trial.","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"R26-1-20210208","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF).","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"R27-1-20210208","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"R28-1-20210208","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"R29-1-20210208","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"key":"R30-1-20210208","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"key":"R31-1-20210208","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijcard.2005.02.016","article-title":"Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition","volume":"106","author":"vand de Wal","year":"2006","journal-title":"Int J Cardiol"},{"key":"R32-1-20210208","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0735-1097(02)01689-3","article-title":"Gradual reactivation over time of vascular tissue angiotensin I to angiotensin II conversion during chronic lisinopril therapy in chronic heart failure","volume":"39","author":"Farquharson","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"R33-1-20210208","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1056\/NEJMoa050496","article-title":"The effect of cardiac resynchronization on morbidity and mortality in heart failure","volume":"352","author":"Cleland","year":"2005","journal-title":"N Engl J Med"},{"key":"R34-1-20210208","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.ejheart.2007.09.002","article-title":"Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure","volume":"9","author":"Seed","year":"2007","journal-title":"Eur J Heart Fail"},{"key":"R35-1-20210208","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/CIRCHEARTFAILURE.107.740704","article-title":"Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure","volume":"1","author":"McMurray","year":"2008","journal-title":"Circ Heart Fail"},{"key":"R36-1-20210208","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N Engl J Med"},{"key":"R37-1-20210208","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jacc.2008.10.036","article-title":"The sudden demise of dual renin-angiotensin system blockade or the soft science of the surrogate end point","volume":"53","author":"Messerli","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R38-1-20210208","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Effect of telmisartan on renal outcomes: a randomized trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"R39-1-20210208","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1097\/HJH.0b013e328333146d","article-title":"Reappraisal of European guidelines on hypertension management: a European Society Hypertension Task Force document","volume":"27","author":"Mancia","year":"2009","journal-title":"J Hypertens"},{"key":"R40-1-20210208","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1056\/NEJMoa042934","article-title":"Combination of isosorbide dinitrate and hydralazine in blacks with heart failure","volume":"351","author":"Taylor","year":"2004","journal-title":"N Engl J Med"}],"container-title":["Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/HJH.0b013e32833984b8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:30:11Z","timestamp":1786041011000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00004872-201008000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/hjh.0b013e32833984b8","relation":{},"ISSN":["0263-6352"],"issn-type":[{"value":"0263-6352","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]}}}